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CASE REPORT
THE MONITORING OF HEMATOPOIETIC STEM CELL TRANSPLANT DONORS AND RECIPIENTS 
FROM ENDEMIC AREAS FOR MALARIA
Juliana INOUE(1), Clarisse Martins MACHADO(2), Giselle Fernandes Maciel de Castro LIMA(1), Maria de Jesus Costa NASCIMENTO(1), 
Vergílio Rensi COLTURATO(2) & Silvia Maria DI SANTI(1)
SUMMARY
Malaria is an unusual complication after hematopoietic stem cell transplantation in non-endemic countries. However, transplant 
candidates, recipients and donors living in endemic regions frequently report previous episodes of malaria. This fact could represent 
an important risk for immunosuppressed recipients that could develop severe malaria cases. We report a case of hematopoietic stem 
cell transplant (HSCT) in which the donor had a history of previous malaria, and close monitoring was performed before and after 
procedure by parasitological and molecular tests. The donor presented Plasmodium vivax in thick blood smears one month after 
transplant and was treated according to Brazilian Health Ministry guidelines. The polymerase chain reaction (PCR) was able to detect 
malaria infection in the donor one week earlier than thick blood film. Even without positive results, the recipient was pre-emptively 
treated with chloroquine in order to prevent the disease. We highlight the importance of monitoring recipients and donors in transplant 
procedures with the aim of reducing the risk of malaria transmission.
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INTRODUCTION
Malaria is an acute infectious illness caused by Plasmodium 
falciparum, P. vivax, P. malariae, P. ovale and more recently P. knowlesi 
was considered the 5th human plasmodia19. Malaria cases due to P. vivax, 
the most prevalent species in Brazil, can present relapses in the absence 
of a new infection. It occurs because the hypnozoites, the dormant forms 
that persist in hepatocytes, can reactivate even after specific treatment and 
lead to a new malaria case. The dynamics of this mechanism is variable 
and the period of dormancy can range from one month to two years11. 
Malaria is an unusual complication after hematopoietic stem 
cell transplantation in non-endemic countries. However, transplant 
candidates, recipients and donors living in endemic regions frequently 
report previous episodes of malaria. In the setting of transplantation, 
transmission may occur by natural exposure to infected mosquitoes, 
or as an induced disease, through contaminated blood products 
or grafts15,18.. Careful investigation of past history of malaria is 
recommended due to the possibility of persistent disease, that can reach 
eight years for P. falciparum,9 three to five years for P. vivax and P. 
ovale and as long as 44 years for P. malariae14. In some non-endemic 
countries, donors who have lived in malaria areas are recommended 
to be deferred from donation for three years or receive empiric 
treatment prior to donating12,17. In endemic regions, a past history of 
malaria is not an exclusion criterion for donation. As post-transplant 
immunosuppression may facilitate parasite reactivation, screening 
before transplant as well as active surveillance with blood tests are 
strongly recommended. The detection of the parasite by thick blood 
smear allows species identification and quantification, nevertheless the 
sensitivity is low, is time consuming and not useful for blood donor 
screening10 or transplantation. However, nested PCR is highly sensitive, 
detecting as few as one parasite per microliter16, and therefore suitable 
for the detection of asymptomatic cases10,12.
Symptomless cases with low parasitemia are due to development of 
immunity in adults, related to endemicity levels of the different areas1,6. 
Some recent reports described symptomless infections, with 70% in Mato 
Grosso5 and 49.5% in Rondonia1, both states in the Brazilian Amazon 
Region. The high prevalence of asymptomatic infections reported in 
Brazil is of great concern as the carriers are source of parasites for vectors 
and also can lead to induced malaria, as reported in a transfusion case, 
where the recipient died as a consequence of P. malariae infection8. 
The case report described here illustrates the complexity of malaria 
management after HSCT. Informed consent was obtained from patient’s 
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family, and the investigational protocol was approved by the Ethics 
Committee before the transplant. 
CASE REPORT
The HSCT recipient and family, including his brother who was the 
only compatible donor available, lived in the city of Manaus located in 
the Amazon rain forest, an endemic region of malaria. While living in the 
endemic area, nine episodes of malaria have been reported by the donor 
during his lifetime, being the last one caused by P. vivax in January 2008. 
Due to the risk of malaria, blood monitoring was proposed to the donor 
and the HSCT recipient during the first three months after the HSCT. 
On July 3rd the donor, living at that time outside of an endemic area, 
presented with P. vivax malaria and was treated with chloroquine base 
in a total dose of 25 mg/kg over three days, and primaquine 0.50 mg/kg/
day during seven days. The haemoscopic examination was negative on 
July 23th 2008. Despite the complete treatment on September 2nd 2008, 
the donor presented symptoms related to malaria. On September 5th 2008 
the donor was diagnosed with P. vivax relapse by thick blood film and 
was treated as previously. 
In October 2008, the transplant candidate, a 6 year-old boy with 
acute lymphocytic leukemia (ALL) in 3rd remission was admitted at 
the Amaral Carvalho Foundation - HSCT Unit to receive an allogeneic 
peripheral blood stem cells (PBSC) transplant from his 15 year-old 
brother. The conditioning regimen consisted of cyclophosphamide 
plus total body irradiation (TBI) and HSCT was performed on October 
16th 2008. Methotrexate and cyclosporine-A (CyA) was introduced for 
graft-versus-host disease (GVHD) prophylaxis. Neutrophil and platelet 
engraftment occurred on days 14 and seven after transplant, respectively. 
On day +10, the recipient presented febrile neutropenia and received 3rd 
generation cephalosporin for approximately 20 days. Blood samples 
from recipient and donor were collected weekly from October 14th 2008 
to December 29th 2008 for blood smears and PCR tests. Thick blood 
films were performed and 2 mL of blood were lysed with 1% saponin 
before DNA extraction with Invisorbâ (Invitek, Berlin) and Brasilica 
(LGC Biotechnology, Brazil) kits. Nested PCR16 was accomplished with 
specific genus and species primers: rPLU5 and rPLU6 for genus and 
rVIV1/rVIV2, rMAL1/rMAL2 and rFAL1/rFAL2 for species (Invitrogen, 
Brazil). Fragments were resolved in 1% agarose gel with Blue Green 
Loading Dye (LGC Biotechnology, Brazil).
From October 14th 2008 to November 4th 2008 thick blood films were 
negative. On November 12th 2008 P. vivax was detected in hemoscopic 
exam of the donor, who was asymptomatic. Retrospective sample 
processing revealed that blood collected one week earlier contained 
malarial DNA (Fig 1). When malaria was diagnosed in the donor, the 
recipient was on day +26 and asymptomatic. Due to the possible risk 
of graft-transmitted malaria, the recipient received chloroquine base 
25 mg/kg over three days. Primaquine was not given to the recipient 
because of the absence of the exoerythrocyte cycle in induced malaria 
cases. The donor was treated with chloroquine base 25 mg/kg over 
three days and primaquine 0.50 mg/kg/day for seven days, with clinical 
and parasitological cure. The HSCT recipient did not develop malaria 
and laboratorial monitoring from patient and donor remained negative 
during follow-up, until December 29th 2008 (Table 1). Unfortunately, the 
recipient died five months after HSCT due to ALL relapse.
DISCUSSION
Despite of the usual complications of transplants, tropical diseases 
as malaria, leishmaniasis, Chagas disease and others remain a challenge 
in endemic countries. Malaria transmission has been reported in kidney7, 
hematopoietic stem cell12 and multiple tissue transplantation4. 
The WHO gold standard method for malaria diagnosis is microscopy. 
It is considered inexpensive and field adapted. Despite being widely 
Table 1
Polymerase chain reaction and thick blood film results according to time post-transplant
 Test pre S day +5 to +13 d+19 d+26 day +33 to +74
Donor TBF -  - - Pv -
 
PCR
 (Pv, Pf, Pm) - - Pv Pv -
Recipient TBF - - - - -
 
PCR 
(Pv, Pf, Pm) - - - - -
pre = pre-transplant; HSCT = Hematopoietic Stem Cell Transplant; PCR = Polymerase Chain Reaction; Pv = Plasmodium vivax; S = day of HSCT; Pm = Plasmodium 
malariae; TBF= Thick Blood Film; Pf = Plasmodium falciparum.
Fig. 1 - Nested PCR based on the amplification of the small-subunit rRNA gene sequence 
of Plasmodium vivax (120 bp). The PCR products were visualized in the 1% agarosis gel 
stained with Blue Green (LGC Biotec.). The DNA was acquired from two different extraction 
methodologies: (1) Invitek, (1a) Brasilica.
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used, it requires specifically trained personnel and is not indicated for 
detection of low parasitemias. Rapid malaria diagnosis tests (RDTs) 
are unsuitable to detect submicroscopic parasitemia because of their 
relatively low sensitivity, mainly for non-P. falciparum malaria2. 
However, asymptomatic cases of persistent malaria may occur and more 
sensitive techniques are necessary to reveal such unsuspected reservoirs 
of malaria. 
This case highlights the importance of sensitive techniques 
in laboratory surveillance of malaria in patients and donors with 
epidemiological risk. Molecular detection methods are more sensitive 
and better adapted to automation allowing objective reading of results. 
In the present case, PCR could detect Plasmodium DNA in donor sample 
one week earlier than the blood film, confirming the diagnosis and 
allowing prophylactic intervention in the recipient. Although nested PCR 
increases the risk of contamination, the protocol chosen in the present 
report is well established, species-specific, able to detect one parasite/
microliter and widely adopted in diagnosis and research of malaria16. 
The risk of contamination can be minimized when assays are carried 
out in well managed and controlled laboratories and with well trained 
and experienced staff, as was the case in this situation.
Pre-transplant screening of donors and recipients from endemic 
regions may not be enough to safely rule out persistent malaria. The 
diagnosis of Plasmodium infection in the donor during the follow up 
occurred just by chance, since he had no symptoms and also this kind 
of monitoring is not part of the routine approach in transplant centers in 
Brazil due to the general unavailability of molecular testing protocols 
locally. In this case, the monitoring was carried out by the Malaria 
Reference Center. Since the patient’s family was planning to stay for 
three months in the city where the HSCT centre is located, we opted to 
monitor the donor who had a recent history of treated malaria. Although 
control tests were negative at pre-transplant screening, blood films and 
PCR turned positive during monitoring. In the follow up period, the donor 
presented with two episodes of malaria without the possibility of external 
reinfection, since he remained in a no transmission area. Relapses are 
due to reactivation of hypnozoites from the pre-erythrocytic cycle and 
can occur despite of complete treatment in a rate that varies from 8% to 
24% in Brazil3. This mechanism can vary depending on P. vivax strain. As 
there are no sufficient data comparing primaquine treatment over seven 
and 14 days, the relapses presented by the HSCT donor could be a result 
of the short scheme used or failure in the drug absorption. This feature 
could lead to undetectable parasitemias and absence of symptoms in the 
beginning of the relapse. Since the HSCT centre city is not a malaria 
region in Brazil, the infection presented by donor was not a consequence 
of a new exposure to infected mosquitoes, but rather represent a case of 
persistent symptomless malaria. Unfortunately, when the diagnosis of 
malaria in the donor was made, the recipient had already received the 
graft and prompt treatment was therefore introduced due to the significant 
risk of malaria. Considering the possibility of malaria transmission 
reported here, the monitoring of donors and/or HSCT recipients living 
in endemic areas by both microscopy and molecular tests may represent 
a safer strategy to prevent graft-transmitted or induced malaria. In the 
absence of laboratory infrastructure, prophylactic treatment might be 
indicated to reduce the risk of infection17. However, in endemic countries 
the administration of antimalarials for donors and recipients could lead 
to unnecessary treatment, especially as some antimalarials present side 
effects. In our experience, none of six donors or recipients with previous 
history of malaria developed the disease after follow-up, which varied 
from one to five years13. Even in non-endemic regions, the high frequency 
of traveling to malaria areas represents a risk of transmission, taking into 
account the possibility of symptomless cases in non-immune patients, 
as occurs in P. malariae infections8.
In this case, the detection of a relapse due to P. vivax in the donor 
revealed by thick blood film and confirmed using PCR allowed 
the prophylactic treatment of the recipient with a safe dosage of 
the antimalarial drug. Importantly, the follow-up of these cases by 
multidisciplinary teams enables better decisions, minimizing the risk 
for the recipient. 
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RESUMO
Monitoramento de doadores e receptores provenientes de áreas 
endêmicas para malária em transplante de células-tronco 
hematopoiéticas
A malária é complicação incomum após o transplante de células-
tronco hematopoiéticas em países endêmicos. No entanto, candidatos 
a transplantes, receptores e doadores que vivem em regiões endêmicas 
frequentemente relatam episódios anteriores de malária. Este fato pode 
representar um risco importante para receptores imunossuprimidos, 
que podem desenvolver casos de malária grave. Relatamos um caso de 
transplante de células-tronco hematopoiéticas (TCTH) em que o doador 
teve história de malária anterior e um monitoramento por meio de exames 
parasitológicos e moleculares foi realizado antes e após o procedimento. 
O doador apresentou Plasmodium vivax na gota espessa um mês após 
o transplante e foi tratado de acordo com as orientações do Ministério 
da Saúde brasileiro. A reação em cadeia da polimerase (PCR) foi capaz 
de detectar a infecção por malária no doador uma semana mais cedo 
do que a gota espessa. Mesmo sem resultados positivos, o receptor foi 
preventivamente tratado com cloroquina, a fim de prevenir as formas 
sanguíneas assexuadas. Destacamos a importância do monitoramento de 
receptores e doadores em procedimentos de transplante, com o objetivo 
de reduzir o risco de transmissão da malária. 
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